Arun A. Rangaswami, MD
Pediatric Hematology-Oncology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Rangaswami’s office at (650) 723-4000 to ask if they take your plan before you enroll.
California Medical Board record
Licence G77258 · Current
Licensed to practise in California · since 1993 · expires 2027-05-31 · Washington University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Pediatrics - Pediatric Hematology-Oncology
Medicaid work
$4,547 in 2024
Medicaid paid $4,547 for 46 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 46 | $4,547 |
| 2024 | 46 | 1 | 12 | $4,547 |
| 2022 | 21 | 1 | 12 | $1,465 |
| 2021 | 93 | 2 | 15 | $7,506 |
| 2020 | 46 | 1 | 12 | $3,278 |
| 2019 | 137 | 3 | 15 | $10,152 |
| 2018 | 338 | 3 | 22 | $31,722 |
See the largest Medicaid services in earlier years
2022
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 21 | $1,465 |
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 78 | $5,859 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 15 | $1,647 |
2020
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 46 | $3,278 |
2019
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 64 | $5,008 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 60 | $3,305 |
| Long return visit (40+ min) | 13 | $1,839 |
2018
| Long return visit (40+ min) | 152 | $18,111 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 135 | $9,335 |
| Return visit (30+ min) | 51 | $4,277 |
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| JAZZ PHARMACEUTICALS INC. · A Phase 3 Randomized Trial for Patients With De Novo Aml Comparing Standard Therapy Including Gemtuzumab Ozogamicin Go To Cpx351 With Go · 2022 | Their institution | $189,525 |
| JAZZ PHARMACEUTICALS INC. · A Study To Compare Standard Chemotherapy To Therapy With Cpx-351 and/Or Gilteritinib for Patients With Newly Diagnosed Aml With Or Without Flt3 Mutations · 2021 | Their institution | $160,057 |
| JAZZ PHARMACEUTICALS INC. · A Study To Compare Standard Chemotherapy To Therapy With Cpx-351 and/Or Gilteritinib for Patients With Newly Diagnosed Aml With Or Without Flt3 Mutations · 2020 | Their institution | $127,030 |
| Incyte Corporation · A Pilot Study of the Immunological Effects of Neo Adjuvant Incb024360 in Patients With Epithelial Ovarian, Fallopian Tube Or Primary Citn-05 Peritoneal Carcinoma · 2020 | Their institution | $57,626 |
| PFIZER INC. · Phase 12 Study To Evaluate Palbociclib Ibrance in Combination With Irinotecan and Temozolomide Or in Combination With Topotecan and Cyclophosphamide in Pediatric Patients With Recurrent Or Refractory Solid Tumors · 2024 | Their institution | $38,602 |
| Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2019 | Their institution | $28,000 |
| E.R. Squibb & Sons, L.L.C. · Coop/Isr Ph I Adolescent Melanoma · 2021 | Their institution | $19,000 |
| JAZZ PHARMACEUTICALS INC. · An Open-Label Study of Jzp-458 (Rc-P) in Patients With Acute Lymphoblastic Leukemia (All)/Lymphoblastic Lymphoma (Lbl) · 2021 | Their institution | $18,500 |
| Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2022 | Their institution | $15,313 |
| Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2021 | Their institution | $14,313 |
| Daiichi Sankyo Inc. · Ac220-A-U202 · 2025 | Their institution | $12,000 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Pivotal Phase 1/2, Single-Arm, Open-Label Study To Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (All) Who Have Relapsed Or Are Resistant Or Intolerant To A Prior Tyrosine Kinase Inhibitor-Containing Therapy, Or Who Have the T315i Mutation · 2022 | Their institution | $11,500 |
| JAZZ PHARMACEUTICALS INC. · An Open-Label Multicenter Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (Rc-P) in Patients With Acute Lymphoblastic Leukemia (All)/Lymphoblastic Lymphoma (Lbl) Following Hypersensitivity To E. Coli-Derived Asparaginases · 2022 | Their institution | $9,151 |
| JAZZ PHARMACEUTICALS INC. · A Phase 3 Randomized Trial for Patients With De Novo Aml Comparing Standard Therapy Including Gemtuzumab Ozogamicin (Go) To Cpx-351 With Go, and the Addition of the Flt3 Inhibitor Gilteritinib for Patients With Flt3 Mutations · 2023 | Their institution | $9,000 |
| JAZZ PHARMACEUTICALS INC. · A Phase 3 Randomized Trial for Patients With De Novo Aml Comparing Standard Therapy Including Gemtuzumab Ozogamicin (Go) To Cpx-351 With Go, and the Addition of the Flt3 Inhibitor Gilteritinib for Patients With Flt3 Mutations · 2024 | Their institution | $8,000 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Pivotal Phase 1/2, Single-Arm, Open-Label Study To Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (All) Who Have Relapsed Or Are Resistant Or Intolerant To A Prior Tyrosine Kinase Inhibitor-Containing Therapy, Or Who Have the T315i Mutation · 2024 | Their institution | $6,000 |
| PFIZER INC. · Phase 12 Study To Evaluate Palbociclib Ibrance in Combination With Irinotecan and Temozolomide Or in Combination With Topotecan and Cyclophosphamide in Pediatric Patients With Recurrent Or Refractory Solid Tumors · 2025 | Their institution | $5,500 |
| JAZZ PHARMACEUTICALS INC. · An Open-Label, Multicenter Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (Rc-P) in Patients With Acute Lymphoblastic Leukemia (All)/Lymphoblastic Lymphoma (Lbl) Following Hypersensitivity To E. Coli-Derived Asparaginases · 2023 | Their institution | $5,000 |
| PFIZER INC. · A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults With Relapsed Or Refractory Cd22 Bacute Lymphoblastic Leukemia Ball · 2025 | Their institution | $3,000 |
| Daiichi Sankyo Inc. · Ac220-A-U202 · 2021 | Their institution | $2,500 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Pivotal Phase 1/2, Single-Arm, Open-Label Study To Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (All) Who Have Relapsed Or Are Resistant Or Intolerant To A Prior Tyrosine Kinase Inhibitor-Containing Therapy, Or Who Have the T315i Mutation · 2023 | Their institution | $2,000 |
| E.R. Squibb & Sons, L.L.C. · Phase II Pediatric Ph+ All - A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib Added To Standard Chemotherapy in Pediatric Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia · 2024 | Their institution | $1,200 |
| Daiichi Sankyo Inc. · Ac220-A-U202 · 2022 | Their institution | $1,000 |
| Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2024 | Their institution | $1,000 |
| Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2023 | Their institution | $1,000 |
| Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2025 | Their institution | $1,000 |
| E.R. Squibb & Sons, L.L.C. · Coop/Isr Ph I Adolescent Melanoma · 2023 | Their institution | $1,000 |
Professional record
- NPI
- 1326173642
- Licence
- CA G77258California G77258: Current · expires 2027-05-31
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G772580
- Taxonomy
- Federal specialty code 2080P0207X (2080P0207X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2007-02-23
- NPI last updated
- 2017-12-21
This is when the NPI record was last certified, not a medical board exam.